

**Vaccines and Related Biological Products
Advisory Committee Meeting
March 7, 2019**

**Dengue Tetravalent Vaccine, Live
Dengvaxia**

Applicant: Sanofi Pasteur

**Kirk Prutzman, Ph.D.
Office of Vaccines Research and
Review/CBER/FDA/DHHS**

Questions to the Committee

3. Are the available data adequate to support the effectiveness of Dengvaxia for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in persons 9 to <17 years of age with laboratory-confirmed previous dengue infection and living in endemic areas?

Please vote Yes or No.

Questions to the Committee

4. Are the available data adequate to support the safety of Dengvaxia when administered to persons 9 through <17 years of age with laboratory-confirmed previous dengue infection and living in endemic areas?

Please vote Yes or No.